VESPER试验中总生存的预后因素:基底分子亚型是关键因素
VESPER试验纳入437例接受新辅助化疗联合膀胱切除术的肌层浸润性膀胱癌患者,其中297例可行中央病理与分子分型评估。单因素分析显示肌酐清除率、淋巴血管侵犯、神经周围侵犯和分子亚型与总生存相关,基底/鳞状亚型预后价值最高且独立于治疗臂。具备两个及以上上述因素者5年总生存率仅38%。
要点
- 基底/鳞状分子亚型是总生存最显著的预后因素,独立于治疗臂。
- 肌酐清除率、淋巴血管侵犯、神经周围侵犯与分子亚型互补预测总生存。
- 无或仅有一个上述因素者5年总生存率分别为72%和67%,两个及以上者为38%。
核心结论
- 在VESPER试验的新辅助化疗人群中识别出四个总生存预后因素,基底分子亚型为最显著且独立于治疗臂的预后因素,尤其在第一年内预后价值高。
研究设计与样本
- VESPER试验(NCT01812369)新辅助化疗人群共437例,其中218例接受剂量密集MVAC方案,219例接受吉西他滨联合顺铂方案。
- 297例尿路上皮癌病例的肿瘤切片和FFPE块可行中央审查,分析临床、生物学、病理和分子特征对总生存的影响。
主要发现
- 单因素分析显示肌酐清除率、淋巴血管侵犯、神经周围侵犯和分子亚型与总生存预后相关。
- 基底/鳞状分子亚型是唯一在1年、3年和5年时间依赖ROC曲线下面积中整个置信区间均大于0.5的协变量,提示高预后价值。
- 多因素分析显示上述四个预后因素对总生存预测具有互补性。
- 无上述因素组5年总生存率为72%(95%CI 63-82%),仅有一个因素组为67%(95%CI 59-76%),两个及以上因素组为38%(95%CI 28-53%)。
临床怎么用
- 可将肌酐清除率、淋巴血管侵犯、神经周围侵犯和基底/鳞状分子亚型联合用于肌层浸润性膀胱癌接受新辅助化疗患者的总生存风险分层。
局限性
- 分子分型与中央审查仅限297例尿路上皮癌病例,非全部437例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Our aim was to identify potential prognostic factors for overall survival (OS) for patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy (NAC) and cystectomy in the VESPER trial (NCT01812369). METHODS: We focused on the NAC VESPER population (n = 437), including 218 patients who received dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, and 219 who received gemcitabine and cisplatin. Tumor slides and formalin-fixed, paraffin-embedded blocks were available for central review in 297 cases of urothelial carcinoma. We investigated the effect of clinical, biological, pathological, and molecular characteristics on OS. KEY FINDINGS AND LIMITATIONS: Univariate analysis identified creatinine clearance, lymphovascular invasion, perineural invasion, and molecular subtype as factors with prognostic relevance for OS. Basal/squamous molecular subtype was the only covariate with the entire confidence interval greater than 0.5 for the time-dependent area under the receiver operating characteristic curve at 1, 3, and 5 yr, which suggests high prognostic value. Multivariable analysis demonstrated that these four prognostic factors were complementary for OS prediction. We did not observe a major difference in the 5-yr OS rate between groups with none of these factors (72%, 95% confidence interval [CI] 63-82%) or only one factor (67%, 95% CI 59-76%). By contrast, the 5-yr OS rate was lower for the group with two or more factors (38%, 95% CI 28-53%). CONCLUSIONS AND CLINICAL IMPLICATIONS: We identified four factors prognostic for OS for patients with MIBC treated with NAC in VESPER. Basal molecular subtype was the most significant prognostic factor for OS, as it was independent of the treatment arm, and showed high prognostic value, in particular during the first year after randomization.
引用
- Pfister C, Harter V, Fontugne J, et al. Prognostic Factors for Overall Survival in the VESPER Trial: Basal Molecular Subtype Is a Relevant Key Factor. Eur Urol Oncol. 2026. PMID: 41577609. doi:10.1016/j.euo.2026.01.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。